Show simple item record

dc.contributor.authorNguyen, Thao H.P.
dc.contributor.authorFagerland, Morten
dc.contributor.authorDeyab, Gia
dc.contributor.authorHjeltnes, Gunnbjørg
dc.contributor.authorHollan, Ivana
dc.contributor.authorFeinberg, Mark W.
dc.contributor.authorEilertsen, Gro Østli
dc.contributor.authorMikkelsen, Knut
dc.contributor.authorAgewall, Stefan
dc.date.accessioned2022-02-15T10:08:00Z
dc.date.available2022-02-15T10:08:00Z
dc.date.issued2021-06-25
dc.description.abstractBackground: Patients with autoimmune arthritis (AA) are at increased risk for impaired cardiac function and heart failure. This may be partly due to the effect of inflammation in heart function. The impact of antirheumatic drugs on cardiac dysfunction in AA remains controversial. Therefore, we aimed to examine effects of antirheumatic treatment on serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in AA patients and its relationship to inflammatory markers.<p><p> Methods: We examined 115 patients with AA (64 rheumatoid arthritis (RA), 31 psoriatic arthritis and 20 ankylosis spondylitis) starting with methotrexate (MTX) monotherapy or tumor necrosis factor inhibitors (TNFi) with or without MTX co-medication. NT-proBNP (measured in serum by ECLIA from Roche Diagnostics), and other clinical and laboratory parameters were evaluated at baseline, after 6 weeks and 6 months of treatment.<p><p> Results: NT-proBNP levels did not change significantly after 6 weeks and 6 months of antirheumatic therapy (pbaseline-6weeks = 0.939; pbaseline-6months = 0.485), although there was a modest improvement from 6 weeks to 6 months in the MTX only treatment group (median difference = -18.2 [95% CI = -32.3 to -4.06], p = 0.013). There was no difference in the effects of MTX monotherapy and TNFi regimen on NT-proBNP levels. The changes in NT-proBNP after antirheumatic treatment positively correlated with changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Baseline NT-proBNP levels were related to baseline CRP and ESR levels, and some other established markers of disease activities in crude analyses. <p><p>Conclusion: Circulating levels of NT-proBNP were related to established inflammatory markers at baseline, and the changes in NT-proBNP after antirheumatic treatment were positively related to these markers. Nevertheless, antirheumatic therapy did not seem to affect NT-proBNP levels compared to baseline, even though inflammatory markers significantly improved.en_US
dc.identifier.citationNguyen, Fagerland, Deyab, Hjeltnes, Hollan, Feinberg, Eilertsen, Mikkelsen K, Agewall S. Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis. PLOS ONE. 2021;16(6)en_US
dc.identifier.cristinIDFRIDAID 1967078
dc.identifier.doi10.1371/journal.pone.0253793
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/10037/24052
dc.language.isoengen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.journalPLOS ONE
dc.relation.urihttps://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0253793
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleAntirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritisen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record